Relmada Therapeutics, Inc. (RLMD)

NASDAQ: RLMD · Real-Time Price · USD

4.210

+0.050 (1.20%)

At close: Nov 13, 2026, 4:00 PM EST

4.161

-0.050 (-1.18%)

After-hours: Nov 13, 2026, 7:30 PM EST

Relmada Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	5.72	3.5	3.86	4.09	5.4	44.44
Short-Term Investments	196.4	89.51	41.05	92.23	142.93	167.47
Cash & Short-Term Investments	202.12	93.01	44.91	96.32	148.32	211.91
Cash Growth	1355.54%	107.10%	-53.38%	-35.06%	-30.01%	80.98%
Other Receivables	0.01	-	-	-	0.51	0.09
Receivables	0.01	-	-	-	0.51	0.09
Prepaid Expenses	2.92	0.98	0.89	1.19	4.04	11.3
Total Current Assets	205.05	93.98	45.8	97.51	152.87	223.3
Other Long-Term Assets	0.25	0.02	0.02	0.04	0.03	0.03
Total Assets	205.3	94	45.82	97.55	152.91	223.33

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	2.54	1.57	4.13	3.51	5.26	11.19
Accrued Expenses	5.24	4.86	6.16	8.69	7.21	3.87
Total Current Liabilities	7.78	6.43	10.29	12.19	12.47	15.06
Other Long-Term Liabilities	3.78	1.06	0	-	-	-
Total Liabilities	11.56	7.49	10.3	12.19	12.47	15.06

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.11	0.07	0.03	0.03	0.03	0.03
Additional Paid-In Capital	937.73	784.71	676.37	646.23	602.52	513.3
Retained Earnings	-744.1	-698.27	-640.88	-560.9	-462.11	-305.07
Shareholders' Equity	193.74	86.51	35.52	85.36	140.44	208.26
Total Liabilities & Equity	205.3	94	45.82	97.55	152.91	223.33

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Cash (Debt)	202.12	93.01	44.91	96.32	148.32	211.91
Net Cash Growth	1355.54%	107.10%	-53.38%	-35.06%	-30.01%	80.98%
Net Cash Per Share	2.17	2.36	1.49	3.20	5.01	12.07
Filing Date Shares Outstanding	106.69	104.89	33.19	30.17	30.1	29.37
Total Common Shares Outstanding	106.69	73.33	30.1	30.1	30.1	27.74
Working Capital	197.27	87.55	35.5	85.31	140.4	208.24
Book Value Per Share	1.82	1.18	1.18	2.84	4.67	7.51
Tangible Book Value	193.74	86.51	35.52	85.36	140.44	208.26
Tangible Book Value Per Share	1.82	1.18	1.18	2.84	4.67	7.51

SEC Filings: 10-K · 10-Q